Sugi Predict

Sugi Predict / Compounds / SCHEMBL4259665

SCHEMBL4259665

SCHEMBL4259665

N#CN(C(=N)N)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.40
▸ PRSS1 P07477 1/20 0.40
▸ PRSS2 P07478 1/20 0.40
▸ C1S P09871 1/20 0.40
▸ PRSS3 P35030 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ F2 P00734 1/20 0.38
▸ F10 P00742 1/20 0.38
▸ F12 P00748 1/20 0.38
▸ F7 P08709 1/20 0.38
▸ F3 P13726 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ BLM P54132 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ HTR3E A5X5Y0 1/20 0.34
▸ HTR3B O95264 1/20 0.34
▸ HTR3A P46098 1/20 0.34
▸ HTR3D Q70Z44 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8854244 0.89 KMT2A (0.31) KMT2APRSS1PRSS2C1SPRSS3
SCHEMBL16679199 0.81 F2 (0.44) KMT2APRSS1PRSS2C1SPRSS3
SCHEMBL7696711 0.80 CHRM5 (0.35) KMT2AALDH1A1MEN1POLBLMNA
SCHEMBL2378818 0.80 LMNA (0.41) KMT2AALDH1A1HTR3EHTR3BHTR3A
SCHEMBL7426969 0.79 ALDH1A1 (0.54) KMT2ARECQLALDH1A1MEN1POLB
SCHEMBL7362598 0.79 ALDH1A1 (0.39) KMT2APRSS1PRSS2C1SPRSS3
SCHEMBL27328134 0.79 NPSR1 (0.41) KMT2ARECQLALDH1A1BLMMEN1
SCHEMBL2420665 0.79 POLB (0.36) KMT2APRSS1PRSS2C1SPRSS3
SCHEMBL19371450 0.78 C1S (0.44) C1SALDH1A1HTR3EHTR3BHTR3A
SCHEMBL19371437 0.78 POLB (0.44) KMT2AALDH1A1F7F3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113149917-B Preparation method of triazine compound 浙江工业大学 2023-01-10 — — CN claimed
CN-113149917-A Preparation method of triazine compound 浙江工业大学 2021-07-23 — — CN claimed
EP-2702045-B1 NOVEL PROCESS FOR THE PREPARATION OF ETRAVIRINE MYLAN LABORATORIES LTD (IN) 2017-10-18 — — EP claimed
EP-2702045-A1 NOVEL PROCESS FOR THE PREPARATION OF ETRAVIRINE Mylan Laboratories, Limited (IN) 2014-03-05 — — EP claimed
US-8653266-B2 Process for the production of etravirine MYLAN LABORATORIES LIMITED (IN) 2014-02-18 — — US claimed
US-20130116433-A1 PROCESS FOR THE PRODUCTION OF ETRAVIRINE MYLAN LABORATORIES LIMITED (IN) 2013-05-09 — — US claimed
WO-2012147104-A1 NOVEL PROCESS FOR THE PREPARATION OF ETRAVIRINE MYLAN LABORATORIES LTD (IN) 2012-11-01 — — WO claimed
CN-1232398-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 1999-10-20 — — CN claimed
CN-1198489-A Composition having no formol used for nonwoven cloth ROHM & HAAS (US) 1998-11-11 — — CN claimed
CN-111848494-B Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2023-08-01 — — CN disclosed
US-11576845-B2 Methods of removing spores comprising alcohol, acrylate copolymer particles, and a cationic coated article 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-02-14 — — US disclosed
CN-113149917-B Preparation method of triazine compound 浙江工业大学 2023-01-10 — — CN disclosed
US-11491255-B2 Removable film forming gel compositions and methods for their application 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-11-08 — — US disclosed
US-11123267-B2 Dental retraction composition with guanidinyl-containing polymer 3M INNOVATIVE PROPERTIES COMPANY (US) 2021-09-21 — — US disclosed
US-20040039001-A1 2-guanidino-4-aryl-quinazoline MERCK PATENT GMH (DE) 2004-02-26 — — US disclosed
CN-1452483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 2003-10-29 — — CN disclosed
EP-1315704-A1 2-GUANIDINO-4-ARYL-QUINAZOLINE MERCK PATENT GmbH (DE) 2003-06-04 — — EP disclosed
CN-1104520-C Composition having no formol used for nonwoven cloth ROHM & HAAS (US) 2003-04-02 — — CN disclosed
WO-2002020496-A1 2-GUANIDINO-4-ARYL-QUINAZOLINE MERCK PATENT GMBH (DE) 2002-03-14 — — WO disclosed
CN-1198489-A Composition having no formol used for nonwoven cloth ROHM & HAAS (US) 1998-11-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11491255-B2 Removable film forming gel compositions and methods for their application CUTA, COL1A1, BLM KMT2A 1041/4885PRSS1 1824/4885PRSS2 676/4885
US-11576845-B2 Methods of removing spores comprising alcohol, acrylate copolymer particles, and a cationic coated article ACR, CUTA, PRKDC KMT2A 4289/4885PRSS1 3466/4885PRSS2 2916/4885
US-20040039001-A1 2-guanidino-4-aryl-quinazoline NHERF1, SLC9A3, SLC9A5 KMT2A 3216/4885PRSS1 2830/4885PRSS2 2756/4885
US-11123267-B2 Dental retraction composition with guanidinyl-containing polymer GMPS, PRMT9, PRMT5 KMT2A 2298/4885PRSS1 3330/4885PRSS2 2889/4885
US-20130116433-A1 PROCESS FOR THE PRODUCTION OF ETRAVIRINE MCM4, EIF2AK2, EIF5B KMT2A 1410/4885PRSS1 3250/4885PRSS2 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.